Cargando…

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification

BACKGROUND: Plasma HIV-1 RNA levels (pVLs), routinely used for clinical management, are influenced by measurement error (ME) due to physiologic and assay variation. OBJECTIVE: To assess the ME of the COBAS HIV-1 Ampliprep AMPLICOR MONITOR ultrasensitive assay version 1.5 and the COBAS Ampliprep Taqm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Viviane D., Wang, Lu, Brumme, Chanson, Wu, Lang, Montaner, Julio S. G., Harrigan, P. Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289538/
https://www.ncbi.nlm.nih.gov/pubmed/28152073
http://dx.doi.org/10.1371/journal.pone.0171155
_version_ 1782504511113265152
author Lima, Viviane D.
Wang, Lu
Brumme, Chanson
Wu, Lang
Montaner, Julio S. G.
Harrigan, P. Richard
author_facet Lima, Viviane D.
Wang, Lu
Brumme, Chanson
Wu, Lang
Montaner, Julio S. G.
Harrigan, P. Richard
author_sort Lima, Viviane D.
collection PubMed
description BACKGROUND: Plasma HIV-1 RNA levels (pVLs), routinely used for clinical management, are influenced by measurement error (ME) due to physiologic and assay variation. OBJECTIVE: To assess the ME of the COBAS HIV-1 Ampliprep AMPLICOR MONITOR ultrasensitive assay version 1.5 and the COBAS Ampliprep Taqman HIV-1 assay versions 1.0 and 2.0 close to their lower limit of detection. Secondly to examine whether there was any evidence that pVL measurements closest to the lower limit of quantification, where clinical decisions are made, were susceptible to a higher degree of random noise than the remaining range. METHODS: We analysed longitudinal pVL of treatment-naïve patients from British Columbia, Canada, during their first six months on treatment, for time periods when each assay was uniquely available: Period 1 (Amplicor): 08/03/2000–01/02/2008; Period 2 (Taqman v1.0): 07/01/2010–07/03/2012; Period 3 (Taqman v2.0): 08/03/2012–30/06/2014. ME was estimated via generalized additive mixed effects models, adjusting for several clinical and demographic variables and follow-up time. RESULTS: The ME associated with each assay was approximately 0.5 log(10) copies/mL. The number of pVL measurements, at a given pVL value, was not randomly distributed; values ≤250 copies/mL were strongly systematically overrepresented in all assays, with the prevalence decreasing monotonically as the pVL increased. Model residuals for pVL ≤250 copies/mL were approximately three times higher than that for the higher range, and pVL measurements in this range could not be modelled effectively due to considerable random noise of the data. CONCLUSIONS: Although the ME was stable across assays, there is substantial increase in random noise in measuring pVL close to the lower level of detection. These findings have important clinical significance, especially in the range where key clinical decisions are made. Thus, pVL values ≤250 copies/mL should not be taken as the “truth” and repeat pVL measurement is encouraged to confirm viral suppression.
format Online
Article
Text
id pubmed-5289538
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-52895382017-02-17 Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification Lima, Viviane D. Wang, Lu Brumme, Chanson Wu, Lang Montaner, Julio S. G. Harrigan, P. Richard PLoS One Research Article BACKGROUND: Plasma HIV-1 RNA levels (pVLs), routinely used for clinical management, are influenced by measurement error (ME) due to physiologic and assay variation. OBJECTIVE: To assess the ME of the COBAS HIV-1 Ampliprep AMPLICOR MONITOR ultrasensitive assay version 1.5 and the COBAS Ampliprep Taqman HIV-1 assay versions 1.0 and 2.0 close to their lower limit of detection. Secondly to examine whether there was any evidence that pVL measurements closest to the lower limit of quantification, where clinical decisions are made, were susceptible to a higher degree of random noise than the remaining range. METHODS: We analysed longitudinal pVL of treatment-naïve patients from British Columbia, Canada, during their first six months on treatment, for time periods when each assay was uniquely available: Period 1 (Amplicor): 08/03/2000–01/02/2008; Period 2 (Taqman v1.0): 07/01/2010–07/03/2012; Period 3 (Taqman v2.0): 08/03/2012–30/06/2014. ME was estimated via generalized additive mixed effects models, adjusting for several clinical and demographic variables and follow-up time. RESULTS: The ME associated with each assay was approximately 0.5 log(10) copies/mL. The number of pVL measurements, at a given pVL value, was not randomly distributed; values ≤250 copies/mL were strongly systematically overrepresented in all assays, with the prevalence decreasing monotonically as the pVL increased. Model residuals for pVL ≤250 copies/mL were approximately three times higher than that for the higher range, and pVL measurements in this range could not be modelled effectively due to considerable random noise of the data. CONCLUSIONS: Although the ME was stable across assays, there is substantial increase in random noise in measuring pVL close to the lower level of detection. These findings have important clinical significance, especially in the range where key clinical decisions are made. Thus, pVL values ≤250 copies/mL should not be taken as the “truth” and repeat pVL measurement is encouraged to confirm viral suppression. Public Library of Science 2017-02-02 /pmc/articles/PMC5289538/ /pubmed/28152073 http://dx.doi.org/10.1371/journal.pone.0171155 Text en © 2017 Lima et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lima, Viviane D.
Wang, Lu
Brumme, Chanson
Wu, Lang
Montaner, Julio S. G.
Harrigan, P. Richard
Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
title Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
title_full Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
title_fullStr Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
title_full_unstemmed Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
title_short Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
title_sort estimation of measurement error in plasma hiv-1 rna assays near their limit of quantification
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289538/
https://www.ncbi.nlm.nih.gov/pubmed/28152073
http://dx.doi.org/10.1371/journal.pone.0171155
work_keys_str_mv AT limavivianed estimationofmeasurementerrorinplasmahiv1rnaassaysneartheirlimitofquantification
AT wanglu estimationofmeasurementerrorinplasmahiv1rnaassaysneartheirlimitofquantification
AT brummechanson estimationofmeasurementerrorinplasmahiv1rnaassaysneartheirlimitofquantification
AT wulang estimationofmeasurementerrorinplasmahiv1rnaassaysneartheirlimitofquantification
AT montanerjuliosg estimationofmeasurementerrorinplasmahiv1rnaassaysneartheirlimitofquantification
AT harriganprichard estimationofmeasurementerrorinplasmahiv1rnaassaysneartheirlimitofquantification